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Abstract
 
Intrathymic expression of tissue-specific antigens (TSAs) by medullary thymic epithelial cells
(Mtecs) leads to deletion of autoreactive T cells. However, because Mtecs are known to be
poor antigen-presenting cells (APCs) for tolerance to ubiquitous antigens, and very few Mtecs ex-
press a given TSA, it was unclear if central tolerance to TSA was induced directly by Mtec antigen
presentation or indirectly by thymic bone marrow (BM)-derived cells via cross-presentation.
We show that professional BM-derived APCs acquire TSAs from Mtecs and delete autoreactive
CD8 and CD4 T cells. Although direct antigen presentation by Mtecs did not delete the CD4
T cell population tested in this study, Mtec presentation efficiently deleted both monoclonal
and polyclonal populations of CD8 T cells. For developing CD8 T cells, deletion by BM-derived
APC and by Mtec presentation occurred abruptly at the transitional, CD4
 
high 
 
CD8
 
low 
 
TCR
 
intermediate
 
stage, presumably as the cells transit from the cortex to the medulla. These studies reveal a coopera-
tive relationship between Mtecs and BM-derived cells in thymic elimination of autoreactive T
cells. Although Mtecs synthesize TSAs and delete a subset of autoreactive T cells, BM-derived
cells extend the range of clonal deletion by cross-presenting antigen captured from Mtecs.
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Introduction
 
Central tolerance is induced in the thymus, where devel-
oping thymocytes that recognize self-peptide–MHC com-
plexes with too high affinity are deleted. For decades, immu-
nologists have tried to understand the roles of thymic
epithelial cells (tecs) and BM-derived cells in negative se-
lection. Studies analyzing [Parent
 
→
 
F
 
1
 
] BM chimeras or
thymus-grafted animals conclusively demonstrated that BM-
derived cells are strong inducers of thymic tolerance, whereas
tolerance induction by tecs is incomplete (1, 2). Most of
these experiments analyzed central tolerance to antigens that
are widely expressed in many or all tissues.
Recent reports have renewed interest in the cell biology
of negative selection by showing that in both human and
mouse, medullary tecs (Mtecs) express a broad range of anti-
gens (for example, insulin), whose expression was previ-
ously thought to be restricted to peripheral tissues (3–6).
Importantly, there is growing evidence that Mtec expression
of tissue-specific antigens (TSAs) leads to deletion of autoreac-
tive T cells. Thymic expression of some TSAs is dependent
on the autoimmune regulator protein (AIRE), and AIRE
deficiency results in organ-specific autoimmune disease (7,
8). In fact, humans expressing mutations in AIRE develop
multi-organ autoimmune disease (9). In addition, transgenic
antigen, driven off tissue-specific promoters, results in thymic
expression of antigen and elimination of T cells reactive
against these antigens (10, 11). Interestingly, such T cells are
rescued from deletion when they develop in AIRE-deficient
thymuses (12). Taken together, these data demonstrate that
there is strong central tolerance to TSA and that this process
is required for the maintenance of self-tolerance.
The thymic APC that mediates tolerance to TSA remains
unresolved. If Mtecs express TSAs yet are poor inducers of
tolerance, then how are T cells reactive against TSAs elim-
inated? This problem is particularly acute for ectopic TSAs,
which appear to be turned on in only 1–5% of Mtecs (3, 5,
13, 14). Based on these findings, we hypothesized that al-
though Mtecs synthesize TSAs, they do not directly present
antigen to delete TSA-reactive T cells. Rather, Mtecs
could act as TSA reservoirs for professional BM-derived
APCs, probably thymic DCs, which would capture TSAs
from Mtecs, process the antigen, and cross-present the TSA
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epitopes to delete autoreactive thymocytes. The results
from our studies show that DCs can indeed pick up TSAs
from Mtecs and delete autoreactive T cells via cross-pre-
sentation. In addition, we find that Mtecs, surprisingly, can
be strong inducers of tolerance to TSA, although these cells
are limited in their capacity to induce tolerance to all TSA-
reactive T cells tested in this study. Results from our studies
provide a framework to understand the cellular interactions
during negative selection.
 
Materials and Methods
 
Mice.
 
CD45.1 congenics (B6.SJL-
 
Ptprc
 
a
 
Pep3
 
b
 
/BoyJ) were pur-
chased from The Jackson Laboratory. RAG-1
 
 
 
/
 
 
 
, OT-I, OT-
I.K
 
b
 
D
 
b
 
 
 
/
 
 
 
, OT-II, OT-II.IA
 
b
 
 
 
/
 
 
 
, B6, RIP-mOVA, OT-I.K14-
K
 
b
 
.K
 
b
 
D
 
b
 
 
 
/
 
 
 
, OT-I.K14-K
 
b
 
.RIP-mOVA.K
 
b
 
D
 
b
 
 
 
/
 
 
 
, and K14-K
 
b
 
.
RIP-mOVA.K
 
b
 
D
 
b
 
 
 
/
 
  
 
mice were bred and housed in patho-
gen-free facilities at the University of Washington. OT-I and
OT-II mice have transgenic V
 
 
 
2V
 
 
 
5 TCRs specific for
OVA
 
257–264 
 
in the context of H2-K
 
b
 
, and OVA
 
323–329 
 
in the con-
text of IA
 
b
 
, respectively (15, 16). RIP-mOVA mice express a
membrane-bound form of OVA (residues
 
139–385
 
) under control of
the rat insulin promoter (RIP; 17).
To generate K14-K
 
b
 
 transgenic mice, H2-K
 
b 
 
cDNA was cloned
into the BamHI site of the K14 promoter construct (provided by
E. Fuchs, University of Chicago, Chicago, IL), followed by exci-
sion of the EcoRI fragment and injection into FVB 
 
  
 
B6 em-
bryos. Founder mice were crossed onto an MHC class I–deficient
background, H2-K
 
b
 
D
 
b
 
 
 
/
 
 
 
, and evaluated for their ability to posi-
tively select a polyclonal repertoire of CD8 as well as OT-I cells.
 
Purification of tecs.
 
Thymuses from 25 mice, ages 3–12 wk,
were diced and gently agitated with a magnetic stir bar in 50 ml
RPMI 1640 plus 5% FCS at 25
 
 
 
C for 20 min to remove thy-
mocytes. The thymic fragments were then incubated for 20 min
with agitation at 30
 
 
 
C in 15 ml RPMI 1640 solution containing
20 mM Hepes, 2% FCS, 0.2 mg/ml collagenase I, and 25 
 
 
 
g/ml
DNase I. After this step, the thymic fragments were saved and in-
cubated for 20 min with agitation at 30
 
 
 
C in 15 ml RPMI 1640
solution containing 20 mM Hepes, 2% FCS, 0.2 mg/ml collage-
nase IV, 0.2 mg/ml dispase, and 25 
 
 
 
g/ml DNase I. This step was
repeated twice, and the supernatants that contained dissociated
tecs were saved, while the remaining thymic fragments were incu-
bated for 25 min with agitation at 37
 
 
 
C in PBS containing 0.5
mM EDTA, 0.05% trypsin, and 50 
 
 
 
g/ml DNase I. The superna-
tants from this tyrpsin digest were combined with the supernatants
from the collagenase/dispase digests and were washed twice in
RPMI 1640/5% FCS, before being placed on a discontinuous
percol density gradient for further tec enrichment. The low den-
sity fractions were saved and washed twice with RPMI 1640/5%
FCS before staining with anti–CD45-PE, anti–Ep-CAM–Alexa
Flour 647, and anti–CDR-1-DIG:anti-DIG FITC. Before cell
sorting, cells were resuspended in buffer containing 7AAD (Mo-
lecular Probes) to identify dead or dying cells. Sorted Mtecs were
93% EP-CAM
 
  
 
and CD45/7AAD/CDR-1
 
 
 
. Sorted cortical tecs
(Ctecs) were 70% EP-CAM/CDR-1
 
  
 
and CD45/7AAD
 
 
 
.
 
RNA Isolation and Real-Time PCR.
 
RNA was purified
(Rneasy Micro Kit; QIAGEN) from sorted tecs and made into
cDNA (Sensiscript; QIAGEN) according to the manufacturer’s
instructions.
Real-time PCR was performed with the following primer and
probe sets: HPRT: forward, 5
 
 
 
-TGGAAAGAATGTCTTGAT-
TGTTGAA; reverse, 5
 
 
 
-AGCTTGCAACCTTAACCATT-
TTG; probe, 5
 
 
 
-FAM-CAAACTTTGCTTTCCCTGGTTAA-
GCAGTACAGCTAMRA; CAT L: forward, 5
 
 
 
-CTGTTG-
CTATGGACGCAAGC; reverse, 5
 
 
 
-CAGAACCCCATGGT-
CGAGG; probe, 5
 
 
 
-FAM-TTCAGGCATCTACTATGAAC-
CCAACTGTAGCAG-TAMRA; CAT S: forward, 5
 
 
 
-GCCA-
TTCCTCCTTCTTCTTCTACA; reverse, 5
 
 
 
-CAAGAACAC-
CATGATTCACATTGC; probe, 5
 
 
 
-FAM AAGCGGTGTCT-
ATGATGACCCCTCCTGTA-TAMRA; insulin: forward, 5
 
 
 
-
GACCCACAAGTGGCACAA; reverse, 5
 
 
 
-ATCTACAATGC-
CACGCTTCTG; probe, 5
 
 
 
-FAM-GCCCGGGAGCAGGTG-
ACCTT-TAMRA; and OVA: forward, 5
 
 
 
-TCATGGTATGT-
TGGCAAATATGG; reverse, 5
 
 
 
-TGATTAAAGGAACAAAA-
GAGCACATT; probe, 5
 
 
 
-FAM-AATTGTTTTCCTTGTAC-
CCATATGTAATGGGTCTTGTAMRA.
In a 25-
 
 
 
l reaction, cDNA was incubated with 0.5 
 
 
 
M for-
ward and reverse primers (Invitrogen), 0.2 
 
 
 
M 5
 
 
 
,6-FAM-3
 
 
 
-
TAMRA fluorogenic probe (Biosearch Technologies), and
TaqMan 2
 
  
 
universal PCR Mastermix (Applied Biosystems).
No template controls and no reverse transcriptase controls
were included for each primer/probe set and cDNA set, re-
spectively. Transcript levels were normalized to HPRT levels
before determining the relative expression in the gene of
interest.
 
Generation of BM Chimeras.
 
To generate chimeric mice, 4–6-
wk-old recipient mice were irradiated with 1,000 rads from a
 
137
 
Cs source and i.v. injected 1 d later with CD4- and CD8-
depleted BM cells. Chimeric mice were maintained on antibiotic
water containing neomycin sulfate and polymyxin B sulfate for
2 d before irradiation and 3 wk after irradiation. Mice were ana-
lyzed 8 wk after BM transfer. In experiments presented in Figs. 1,
1–6, BM was depleted of NK1.1
 
  
 
cells. In experiments presented
in Figs. 5 and 6, recipient mice were depleted of NK1.1
 
  
 
cells
(1 d before irradiation recipient mice were injected i.p. with 500
 
 
 
g of the monoclonal antibody PK136).
 
Listeria Monocytogenes Infections.
 
The recombinant 
 
L. monocy-
togenes
 
 strain engineered to secrete chicken OVA (rLmOva) was
provided by H. Shen (University of Pennsylvania School of
Medicine, Philadelphia, PA; reference 18). Frozen stocks of rLm-
Ova were grown in brain–heart infusion broth. Bacteria culture
samples were grown to mid-log phase, measured by OD (A600),
and diluted in PBS for injection. Mice were infected with 2,000
CFUs of rLmOva (19).
 
Intracellular IFN-
 
  
 
Staining.
 
Intracellular IFN-
 
  
 
staining was
performed in accordance with the manufacturer’s instructions
(BD Biosciences). In 96-well plates, 1–2 
 
  
 
10
 
6 
 
cells/well were
stimulated with medium alone (no peptide) or 10
 
 
 
7 
 
M OVA
peptide (SIINFEKL) for 5 h in the presence of 1 
 
 
 
g/ml brefeldin
A. Cells were then washed, stained with anti-CD8 and anti-
Ly5.2 (BD Biosciences), resuspended in permeabilization fixation
buffer, and stained with anti–IFN-
 
  
 
antibody. Labeled cells were
washed in permeabilization buffer, resuspended in 4% para-
formaldehyde buffer, and analyzed by flow cytometry.
 
Results
 
A Polyclonal Repertoire of CD8 T Cells Is Deleted in RIP-
mOVA Thymuses.
 
To study central tolerance to TSA, we
used RIP-mOVA mice that express a membrane-bound
form of OVA under the control of the RIP. In these mice,
OVA is expressed in the pancreas, kidney, and thymus
(specifically by Mtecs, see below; reference 17). The RIP-
mOVA mouse was chosen as a model TSA for three main 
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reasons. First, in multiple RIP transgenic lines, this pro-
moter was shown to be on in rare Mtecs (5). Second, OVA
is membrane bound, which should limit the thymic presen-
tation of antigen to OVA-expressing Mtecs or cells that ac-
quire OVA by interacting with such Mtecs. A major goal
of our studies is to understand if thymic DCs acquire TSA
directly from Mtecs. For this reason, use of a secreted anti-
gen would greatly limit interpretation of our experiments,
given the possibility that thymic DCs, or other cells, could
acquire the antigen through diffusion and endocytosis. The
final reason we chose RIP-mOVA as a model TSA is be-
cause thymic deletion of OVA-specific T cells in these
mice is known to be dependent on the thymic expression
of OVA and is not the result of OVA reaching the thymus
from the periphery, either via blood or from a migrating
APC (20).
To understand if OVA is regulated in the same manner
as insulin or other TSAs, we purified Ctecs and Mtecs from
RIP-mOVA thymuses and assessed the expression of OVA
by real-time PCR. As is the case for other TSAs, we found
that Mtecs are the primary producers of OVA in the RIP-
mOVA thymus (Fig. 1 A). To determine if a polyclonal
repertoire of OVA-specific CD8 T cells is deleted in RIP-
mOVA thymuses, we made use of V
 
 
 
5 transgenic mice
(21). T cells from these mice use the TCR-
 
  
 
chain of the
OVA-specific OT-I TCR and have a high precursor fre-
quency of OVA-specific CD8 T cells (
 
 
 
1-2%; reference
21). Importantly, OVA-specific CD8 T cells in V
 
 
 
5 trans-
genic mice have diverse TCR V
 
  
 
usage, indicating that
OVA-specific CD8 T cells in these mice have a polyclonal
TCR repertoire (21).
To ask whether polyclonal OVA-specific CD8 T cells
are deleted during development in RIP-mOVA thymuses,
we determined whether V
 
 
 
5 transgenic CD8 single posi-
tive (SP) thymocytes from RIP-mOVA mice were capable
of responding to OVA. CD45.1 congenic hosts received
10
 
6 
 
CD8 SP thymocytes from CD45.2
 
  
 
[V
 
 
 
5
 
→
 
B6] or
[V
 
 
 
5
 
→
 
RIP-mOVA] BM-chimeric mice, and were then
immunized with 2,000 
 
L. monocytogenes
 
–expressing OVA
(rLmOva) 1 d later (Fig. 1 B). As expected, we detected a
robust response to OVA from the adoptively transferred
V
 
 
 
5 transgenic CD8 T cells isolated from B6 thymuses
amounting to 
 
 
 
30% of total CD8 cells in the spleen 7 d af-
ter immunization (Fig. 1 C, left panels). In this case, the re-
Figure 1. Expression of OVA by Mtecs
leads to deletion of a polyclonal repertoire
of OVA-specific CD8 T cells. (A) OVA is
selectively expressed in Mtecs in RIP-
mOVA thymuses. Ctecs and Mtecs from
RIP-mOVA thymus were enriched and ex-
pression of OVA was investigated by real-
time PCR. Cathepsin L (Cat L), cathepsin S
(Cat S), and insulin were monitored as con-
trols for cell purity. Ctecs expressed high
levels of cathepsin L, low levels of cathepsin
S, and no insulin. Meanwhile, Mtecs ex-
pressed low levels of cathepsin L, high levels
of cathepsin S, and insulin (reference 3).
(B) Grafting V 5 BM (CD45.2) into lethally
irradiated B6 or RIP-mOVA recipients
generated [V 5→B6] or [V 5→RIP-
mOVA] BM-chimeric thymuses. 8 wk after
BM transfer, 106  CD8 thymocytes were
transferred into wild-type, congenically
marked B6 mice (CD45.1). 1 d later, these
mice were immunized with rLmOva. 7 d
after immunization, splenocytes were iso-
lated and their ability to produce IFN-  was
determined in response to a 5-h incubation
with OVA peptide or medium alone. This
experiment was performed twice with two
mice per group. (C) IFN-   and CD45.2
staining on gated CD8 T cells. Trasfer of
thymocytes from [V 5→B6] is shown in
the left panels. Transfer of thymocytes from
[V 5→RIP-mOVA] is shown in the right
panels. Numbers below indicate percentages
of cells in each quadrant. V 5 transgenic
donor-derived CD8 T cells are CD45.2 ,
whereas host-derived CD8 T cells are
CD45.2 .Central Tolerance to Tissue-specific Antigens 1042
sponse elicited from 106 donor cells is 40 times greater than
the response of the entire host CD8 compartment. In con-
trast, we were unable to detect any CD8 response to OVA
from V 5 transgenic CD8 T cells isolated from RIP-
mOVA thymuses. In this case, only host CD45.2  CD8 T
cells responded (Fig. 1 C, right panels). These results show
that a polyclonal repertoire of OVA-specific CD8 T cells is
efficiently deleted in the RIP-mOVA thymus.
Deletion of CD8 T Cells in RIP-mOVA Thymus Occurs
Late in Development. Use of V 5 transgenic mice in
the previous experiments demonstrated that OVA-specific
CD8 T cells are efficiently deleted when they develop in
RIP-mOVA thymuses. To study the timing of thymic de-
letion more precisely, we monitored the development of
TCR transgenic OT-I T cells in deleting RIP-mOVA or
nondeleting B6 thymuses. Cellularities differed only mod-
estly between these thymuses (B6: 83.0   106   2.6 vs.
RIP-mOVA: 63.7   106   6.4), suggesting that a minor
population of thymocytes is eliminated in the RIP-mOVA
thymus. Gating on the principal populations of OT-I thy-
mocytes, we found that the number of double positive
(DP) thymocytes (DP bright and DP dull) was comparable
between RIP-mOVA and B6 (Fig. 2 A). We consistently
found a modest reduction in the percentage of CD4 SP T
cells in RIP-mOVA compared with B6 thymuses. Most of
these cells have been shown to be transitional cells and pre-
cursors to CD8 SP thymocytes in the OT-I system (22). In
addition, we found a threefold reduction in the percentage
of cells in the CD8 SP gate in RIP-mOVA thymuses. The
remaining CD8 SP thymocytes in the RIP-mOVA thymus
were immature because they expressed high levels of CD24
(heat stable antigen) and low levels of transgene-encoded
TCR (V 2; Fig. 2 B). The bulk of SP CD8 cells in RIP-
mOVA thymuses are therefore precursors to DP cells.
Overall, there is close to a 100-fold reduction in the num-
ber of phenotypically mature CD8 T cells in the RIP-
mOVA thymus compared with the B6 thymus.
Next, we sought to determine at what stage OVA-specific
T cells are deleted in the RIP-mOVA thymus. We gated on
the principal thymocyte populations and used TCR (V 2)
expression level as a maturity marker (Fig. 2 C). DP bright T
cells were comparable in number and phenotype in B6 and
RIP-mOVA thymuses. Next, we looked at DP dull cells that
have undergone an early stage of positive selection and
down-regulated CD4 and CD8. V 2 staining revealed two
distinct populations of DP dull cells in the B6 thymic envi-
ronment, including a relatively immature population that was
TCR intermediate (DP dull TCR  ) and a more mature
population that was TCR high (DP dull TCR    ). In
striking contrast, only the immature DP dull TCR   pop-
ulation was present in RIP-mOVA thymuses, whereas the
DP dull TCR     population was absent. TCR levels
Figure 2. OT-I T cells are deleted late in development in RIP-mOVA thymuses. (A) OT-I transitional cells and CD8 SP thymocytes are reduced in
RIP-mOVA thymuses. Grafting OT-I BM into lethally irradiated B6 or RIP-mOVA recipients generated [OT-I→B6] or [OT-I→RIP-mOVA] BM-
chimeric thymuses. Thymocytes from the indicated mice were analyzed for expression of CD4 and CD8 by flow cytometry. The numbers below indicate
the percentages of cells in each gate. (B) Remaining CD8 SP thymocytes in RIP-mOVA mice are immature. CD24 and TCR (V 2) expression after
gating on CD8 SP thymocytes. Numbers in the quadrants indicate the percentage of mature phenotype cells. Results presented here are representative of
three independent studies with two to four mice per group. (C) V 2 expression by thymocyte populations gated as shown in A. Solid black line repre-
sents thymocytes from RIP-mOVA mice, and shaded gray histograms represent thymocytes from B6 mice. The bar indicates V 2 levels on transitional
thymocytes from B6 mice. (D) Schematic representation of OT-I thymocyte development and postulated stage of deletion in RIP-mOVA thymuses.Gallegos and Bevan 1043
on transitional cells (CD4  TCR   ) in both B6 and
RIP-mOVA thymuses were comparable. The level of TCR
on these transitional thymocytes is intermediate to that on
the two DP dull thymocyte populations found in B6, and is
marked by a bar in Fig. 2 C. Finally, the CD8 SP gated cells
in the B6 thymus contain a majority of TCR     cells,
whereas the cells in the RIP-mOVA thymus contain very
few mature cells (Fig. 2, B and C).
The pathway of T cell development in control mice and
the stage of deletion in the RIP-mOVA thymus that we de-
duce from these results are presented schematically in Fig. 2
D. We conclude that in both B6 and RIP-mOVA thymic
environments, DP bright TCR  T cells are positively se-
lected and become DP dull TCR   T cells. Up to this
point, there is no difference between control and deleting
thymuses. The cells then up-regulate CD4 expression and
develop into transitional cells (CD4  TCR   ). Next,
in the B6 thymus, transitional cells become DP dull
TCR     T cells and eventually give rise to mature
CD8 SP T cells (CD8 TCR    ). In contrast, DP dull
TCR     T cells are undetectable in the RIP-mOVA
thymus, suggesting that deletion occurs just before this stage
of development. Evidence for deletion at the transitional cell
stage comes from the observation that there is a modest yet
consistent reduction in the percentage of transitional (CD4
TCR   ) cells in the RIP-mOVA thymus (Fig. 2 A).
Efficient Deletion of CD8 T Cells in RIP-mOVA Thymus
Does Not Require Antigen Presentation by BM-derived Cells.
To determine if antigen presentation by BM-derived cells
was responsible for the deletion of CD8 T cells in RIP-
mOVA thymuses, we investigated both V 5 and OT-I
transgenic thymocytes developing in environments where
BM-derived cells did not express MHC class I and there-
fore could not present OVA to developing thymocytes.
We generated BM chimeras by grafting MHC class I–defi-
cient V 5 BM (V 5.MHC I / ) into lethally irradiated
RIP-mOVA recipients ([V 5.MHC I / →RIP-mOVA]
BM chimeras) and asked whether V 5 transgenic CD8 SP
thymocytes from these chimeric mice were capable of re-
sponding to OVA. NK1.1-depleted RAG-1 /  hosts re-
ceived 5   105 CD8 SP thymocytes and were immunized
with 2,000 rLmOva 1 d later (Fig. 3 A). We detected ro-
bust responses to OVA from V 5 thymocytes that matured
in B6 thymic environments ([V 5→B6] and [V 5.MHC
I / →B6] BM chimeras; Fig. 3 B). In contrast, we did not
detect any OVA-specific responses from V 5 CD8 T cells
that matured in RIP-mOVA thymic environments in
which BM-derived cells expressed MHC class I ([V 5→
RIP-mOVA] BM chimeras) and, surprisingly, when BM-
derived cells did not express MHC class I ([V 5.MHC I / →
RIP-mOVA] BM chimeras).
Similarly, analysis of OT-I thymocytes that developed in
RIP-mOVA thymic environments in which BM-derived
cells did not express MHC class I ([OT-I.MHC I / →
RIP-mOVA] BM chimeras), revealed that OT-I thy-
mocytes were efficiently deleted in this setting. Thus, the
percentages of CD8 SP thymocytes and phenotypically ma-
ture CD8 SP thymocytes were comparable to that seen in
control RIP-mOVA thymuses in which BM-derived cells
expressed MHC class I (Fig. 4, A and B). These data dem-
onstrate that antigen presentation by BM-derived cells is
not required for the deletion of OVA-specific polyclonal or
monoclonal CD8 thymocytes in the RIP-mOVA thymic
environment, and suggest that Mtec presentation is suffi-
cient to delete OVA-specific CD8 T cells. One problem
with this interpretation is the possibility that host MHC
Figure 3. Deletion of OVA-specific polyclonal CD8 thymocytes does not require antigen presentation by BM-derived cells. (A) Grafting V 5 or
V 5.MHC I /  marrow into lethally irradiated B6 or RIP-mOVA recipients generated [V 5→B6], [V 5→RIP-mOVA], [V 5.MHC I / →B6], and
[V 5.MHC I / →RIP-mOVA] BM-chimeric thymuses. 2–4 mo after BM transfer, 0.5   106 V 5 CD8 thymocytes matured in the indicated thymic
environments were transferred into NK1.1-depleted (i.p. injection of 500  g of the monoclonal antibody PK136) RAG-1 /  mice. 1 d later, these mice
were immunized with rLmOva. To eradicate remaining rLmOVA, on day 4 after immunization, mice were injected i.p. with 1 mg ampicillin and were
given ampicillin in their drinking water (5 mg/ml) for the remainder of the experiment. 7 d after immunization, splenocytes were isolated and their ability to
produce IFN-  was determined in response to a 5-h incubation with OVA peptide or medium alone. (B) IFN-  and CD8 staining on gated CD8 T cells
from the indicated transfers. Numbers indicate percentages of cells within the gate.Central Tolerance to Tissue-specific Antigens 1044
class I–sufficient, BM-derived cells were not completely re-
placed by MHC class I–deficient BM grafts. This is not the
case, however, because we were unable to detect any
MHC class I–bearing thymic DCs from chimeric thymuses
([MHC I   →WT] BM chimeras). This indicates that an-
tigen presentation leading to clonal deletion in chimeric
thymuses is mediated exclusively by Mtecs.
Next, we determined whether the timing of OT-I dele-
tion in the absence of MHC class I–bearing BM cells was
similar to that seen when BM cells expressed MHC class I
(Fig. 2, C and D). We examined expression of V 2 on DP
dull, transitional, and CD8 SP subsets developing in RIP-
mOVA thymuses in which antigen presentation is mediated
exclusively by Mtecs ([OT-I.MHC I   →RIP-mOVA]
BM chimeras). Deletion of OT-I thymocytes occurred
between the transitional TCR     and DP dull
TCR     stages of development at precisely the same
stage observed for cells developing in thymuses in which
both BM and Mtecs expressed MHC class I ([OT-I→RIP-
mOVA] BM chimeras; Fig. 4 C). DP dull TCR    
cells were absent whether or not MHC was expressed on
DCs. In addition, the percentage of transitional cells in
[OT-I.MHC I   →RIP-mOVA] BM chimeric thymuses
was modestly reduced compared with nondeleting B6
thymuses, similar to the reduction seen in [OT-I→RIP-
mOVA] BM chimeric thymuses (Figs. 2 A and 4 A, respec-
tively). In summary, deletion of OT-I cells in the RIP-mOVA
thymus occurs at the transitional stage of development
whether Mtecs mediate deletion exclusively, or Mtecs and
DCs both have the potential to mediate deletion.
BM-derived Cells in the RIP-mOVA Thymus Delete CD8
Thymocytes. The data presented in Fig. 4 demonstrate that
antigen presentation by BM-derived cells is not required
for deletion of OT-I cells developing in RIP-mOVA thy-
muses. Next, we wanted to determine whether BM-
derived cells could acquire OVA from Mtecs and process
and present it to delete OT-I thymocytes. This required a
system in which Mtecs do not express MHC class I, whereas
BM-derived cells express MHC class I. Deletion of OT-I
thymocytes in this setting could only be attributed to anti-
gen presentation by BM-derived cells. However, because
positive selection requires MHC expression on Ctecs, we
generated mice in which thymic expression of MHC class I
is limited to Ctecs. This was accomplished using the keratin
14 promoter to drive the expression of H2-Kb in the Ctecs
of KbDb  /  mice (K14-Kb.MHC I /  mice; 23–25). Posi-
Figure 4. Deletion of OT-I/RIP-mOVA thymocytes does not require antigen presentation by BM-derived cells. Lethally irradiated RIP-mOVA
mice were reconstituted with either OT-I or OT-I.MHC I /  BM. Results presented here are representative of three independent studies with two to
four mice per group. (A) Thymocytes from the indicated mice were analyzed for CD4 and CD8 expression by flow cytometry. The numbers indicate the
percentage of cells in each gate. (B) CD24 and V 2 expression after gating on CD8 SP thymocytes. Numbers in the quadrants indicate the percentage of
mature phenotype cells. (C) V 2 expression was analyzed on DP dull, CD4, and CD8 thymocytes taken from the indicated mice. The data analyzed are
from the gated populations shown in Fig. 2 A for [OT-I→B6] BM chimeras and from the gated populations shown in A for [OT-I→RIP-mOVA] and
[OT-I.MHC I / →RIP-mOVA] BM chimeras. Shaded gray histogram represents the DP dull population, and blue and red lines represent CD4 SP
(transitional) and CD8 SP populations, respectively.Gallegos and Bevan 1045
tive selection of OT-I thymocytes is supported in K14-Kb
transgenic thymuses because there is an increase in the per-
centage of mature (CD8  V 2  CD24low) CD8 thymo-
cytes in K14-Kb transgenic mice (OT-I.K14-Kb.MHC I / )
compared with K14-Kb  mice (OT-I.MHC I / ; Fig. 5, A
and B). Importantly, when OT-I.K14-Kb.MHC I /  mice
were crossed to MHC class I–deficient RIP-mOVA mice
(OT-I.K14-Kb.RIP-mOVA.MHC I /  mice), OT-I thy-
mocytes were not deleted (Fig. 5, A and B, right panels). In
these mice, OT-I DP T cells are positively selected by Kb-
expressing Ctecs, but are not negatively selected by Mtecs
(which express OVA) or BM-derived cells because neither
of these cell types express MHC class I.
Given this result, we next sought to determine whether
MHC class I expression only on DCs could negatively select
OT-I thymocytes. We grafted MHC class I–expressing OT-I
BM into recipient mice that expressed both K14-Kb and
RIP-mOVA ([OT-I→K14-Kb.RIP-mOVA.MHC I / ]
BM chimeras). Compared with chimeras in which neither
BM-derived cells nor Mtecs expressed MHC class I ([OT-
I.MHC I / →K14-Kb.RIP-mOVA.MHC I / ] BM chi-
meras), mature OT-I thymocytes were deleted (Fig. 6, A and
B). There was a reduction in the percentage of cells in the
CD8 SP T cell gate and a further reduction in the percentage
of mature CD24low V 2high thymocytes within this popula-
tion. These results demonstrate that BM-derived cells, most
likely thymic DCs, are able to acquire OVA from Mtecs and
cross-present it to mediate deletion of OT-I thymocytes.
Deletion of CD4 T Cells in RIP-mOVA Thymuses Requires
Antigen Presentation by BM Cells. The data in Figs. 3 and 4
show that Mtecs are potent inducers of tolerance to devel-
oping OVA-specific CD8 T cells. We investigated the abil-
ity of Mtecs to delete OVA-specific CD4 T cells from
MHC class II–restricted OT-II TCR transgenic mice. In
the nondeleting [OT-II→B6] BM chimeric thymuses,
normal numbers of mature CD4 SP thymocytes (CD4 
V 2high CD24low) are detected (Fig. 7, A–C). Analysis of
the deleting [OT-II→RIP-mOVA] BM chimeric thymuses
revealed a reduction in the percentage of CD4 SP thy-
mocytes and a further reduction in the percentage of these
cells that were mature. In contrast, analysis of RIP-mOVA
thymuses in which only Mtecs, and not BM cells, expressed
MHC class II ([OT-II.MHC II / →RIP-mOVA] BM
chimeras), demonstrated that OT-II thymocytes were not
deleted in this setting. Normal numbers of mature pheno-
type CD4 SP T cells were present as shown by a compi-
lation of numbers of mature phenotype CD4  Va2high
CD24low OT-II cells from many mice (Fig. 7 C). This re-
sult demonstrates that Mtecs cannot serve as APCs to delete
OT-II thymocytes in RIP-mOVA thymus. Deletion in this
case is absolutely dependent on DCs picking up OVA from
Mtecs for presentation to developing OT-II thymocytes.
This is in contrast to the situation with OVA-specific CD8
T cells, in which either direct presentation by Mtecs or
cross-presentation by DCs can cause deletion.
Discussion
Mtecs express a broad range of TSA and thymic tolerance
to TSA can be remarkably efficient. The fact that only rare
Mtecs actually express a given TSA ( 1-5% of Mtecs in
cases that have been analyzed; references 3, 5, 11, 13, and
14), plus the fact that epithelial cells might be poor at pre-
senting antigen for T cell deletion, led us to propose that in-
direct or cross-presentation of Mtec-derived TSA by DCs
would be key in inducing efficient central tolerance to TSA.
Figure 5. OT-I CD8 T cells are
positively selected in K14-Kb  thy-
muses and are not negatively se-
lected when RIP-mOVA is also ex-
pressed. Results presented here are
representative of two studies with
one to three mice per group. All
mice are littermates. (A) Thy-
mocytes from the indicated mice
were analyzed for CD4 and CD8
expression. The numbers below in-
dicate the percentage of cells in each
gate. (B) CD24 and V 2 expression
after gating on CD8 SP thymocytes.
Numbers in the quadrants indicate
the percentage of cells with a mature
phenotype.Central Tolerance to Tissue-specific Antigens 1046
This proposal was certainly borne out in the analysis of CD4
T cells expressing the OT-II TCR, where we show that
OVA has to be acquired by DCs to tolerize (Fig. 7).
At this stage we do not know whether this requirement
for antigen presentation by DCs is representative of central
tolerance induction for all developing CD4 thymocytes, or
whether it is peculiar to the OT-II TCR transgenic model.
From older studies of central tolerance induction to ubiqui-
tous antigen (such as allogeneic MHC), there is evidence
that CD4 T cells can be tolerized by tecs. However, in these
cases the tolerizing antigen was expressed by 100% of epi-
thelial cells and there is only one report that has addressed
whether TSAs, possibly synthesized by only 1–5% of Mtecs,
could be directly presented to induce CD4 tolerance. In this
analysis, CD4 TCR transgenic thymocytes did not require
antigen presentation by BM-derived cells to be deleted (13,
26). However, in this report the investigators analyzed tol-
erance to a secreted antigen, making it difficult to know
how many Mtecs or Ctecs were actually presenting this an-
tigen, as it was probable that the secreted TSA could diffuse
throughout the thymus and be taken-up and presented by
Mtecs and Ctecs. It is likely that the deletion in this study
was mediated by Ctecs, and not Mtecs, because deletion
targeted pre-positively selected DP thymocytes that are
known to reside in the cortex and not the medulla (13, 26).
Indeed, a recent report demonstrated that thymocytes were
deleted mostly in the cortex when the antigen was soluble,
whereas deletion occurred mostly in the medulla when the
same antigen was membrane bound (27).
The inability of Mtecs to directly present antigen to de-
lete OT-II thymocytes contrasted with the efficiency of
DC-mediated deletion via antigen capture and could have
a number of explanations. First, DC presentation delivers a
stronger (deleting) signal to the immature thymocyte based
on their superior battery of costimulatory and adhesion
molecules. Although no single accessory molecule has been
shown to be crucial for negative selection, a full investiga-
tion comparing thymic DC and Mtec expression has not
been undertaken (28). Second, in the case of many TSAs,
expression in the thymus medulla might be limited to a
small fraction,  5%, of Mtecs. DCs that capture antigen
from Mtecs may therefore outnumber the number of
Mtecs presenting antigen. Also, DCs may cover a larger
area of the medulla and they may carry antigen to specific
areas. DCs are known to be especially common in the cor-
tico–medullary junction, and this area might be specialized
to allow DCs to present self-antigen to positively selected
cortical thymocytes as they traverse this junction en route
to the medulla. The ability of DCs to capture antigen from
Mtecs and efficiently delete all dangerously self-reactive thy-
Figure 6. BM-derived cells in RIP-
mOVA thymus can efficiently delete OT-I
thymocytes. OT-I.MHC I /  or OT-I BM
was grafted onto lethally irradiated K14-
Kb.RIP-mOVA.MHC I /  recipients. (A)
Thymocytes from the indicated mice were
analyzed for CD4 and CD8 expression. The
numbers below indicate the percentage of
cells in each gate. (B) CD24 and V 2 ex-
pression after gating on CD8 SP thy-
mocytes. Numbers in the quadrants indicate
the percentage of mature phenotype cells.
Results presented here are representative of
two studies with two mice per group.Gallegos and Bevan 1047
mocytes is of key importance in the prevention of au-
toimmune disease. It is likely that a specialized mechanism,
which forces positively selected T cells to run a gauntlet of
cells efficiently presenting self-antigen, would evolve to en-
force deletion of autoreactive T cells.
In contrast to the absolute requirement for professional
APCs to acquire antigen from Mtecs to induce central tol-
erance in the MHC class II–restricted OT-II system, we
find that MHC class I–restricted, OVA-specific thymocytes
can be efficiently deleted by antigen presented directly by
Mtecs as well as by DC cross-presentation (Figs. 3, 4, and
6). The ability of Mtecs to present MHC class I–restricted
OVA and efficiently delete both polyclonal and monoclonal
OVA-specific CD8 thymocytes might be due to high TCR
affinity and/or efficient antigen presentation. Although no
information exists on the TCR affinities of the OVA-spe-
cific CD8 T cells in V 5 transgenic mice, one might predict
that these cells represent a range of TCR affinities, as they
are polyclonal and use multiple TCR-  chains. The affinity
of the OT-I TCR for its ligand has been measured (29) and
might be higher than that of OT-II for its ligand, though no
information exists on the OT-II TCR affinity. Another
possibility to explain Mtec deletion of CD8 but not CD4
thymocytes is that Mtecs that synthesize membrane-bound
OVA might be more efficient at processing and presenting
MHC class I/OVA compared with class II/OVA, though
one would expect that this membrane-bound form of OVA
would readily enter the class II antigen processing and pre-
sentation pathway (30). Finally, the stability of the peptide–
MHC complexes, Kb/OVA257–264 and IAb/OVA323–329, are
likely to differ, with the class I complex being much more
stable than the class II complex.
Two other surprising findings came out of our analysis of
CD8 T cell deletion. One is how abrupt and early after
positive selection deletion occurred. The second is the fact
that direct antigen presentation by Mtecs alone can induce
the same pattern of abrupt, early deletion (Fig. 4). OT-I T
cell development from the DP to the SP stage follows a
similar pattern to that of other CD8 T cells (22, 31). After
positive selection, both CD4 and CD8 expression are
down-regulated (DP dull), then CD4 is up-regulated (tran-
sitional), and then CD4 is down-regulated (DP dull) as
Figure 7. Antigen presentation by BM-derived cells is
required for deletion of OT-II thymocytes in RIP-mOVA
thymus. Lethally irradiated B6 or RIP-mOVA mice were
grafted with either OT-II or OT-II.MHC II /  BM. (A)
Thymocytes from the indicated mice were analyzed for
CD4 and CD8 expression. The numbers indicate the per-
centage of cells in each gate. (B) CD24 and V 2 expression
after gating on CD4 SP thymocytes. Numbers in the
quadrants  indicate the percentage of mature phenotype
cells. (C) Graphic representation of results from three stud-
ies. Each symbol represents data from one mouse.Central Tolerance to Tissue-specific Antigens 1048
these cells finally mature to CD8 SP cells. In step with this
differentiation, the selecting TCR is gradually up-regu-
lated. This “dance” allowed us to pinpoint the stage of
deletion in RIP-mOVA thymuses. Surprisingly, deletion
occurs at the transitional stage when the developing thy-
mocyte expresses 10–30-fold lower levels of the CD8 core-
ceptor, and 2–3-fold lower TCR levels than expressed on
CD8 SP cells (Figs. 2 and 4). Therefore, deletion of TSA-
specific T cells at this stage is remarkably efficient, particu-
larly when we consider that there are extremely low levels
of antigen present in the medulla. Other studies on Nurr77
expression have suggested that transitional thymocytes are
primary targets for negative selection (32).
This pattern of abrupt, early deletion would be consis-
tent with the idea of a “gauntlet” of DCs mediating self-
tolerance at the cortico–medullary junction as positively
selected transitional cells transit from the cortex into the
medulla, except for our finding that direct antigen presen-
tation by Mtecs alone (when DCs do not express MHC
class I) results in the same pattern of deletion (Fig. 4). We
must assume in this case that transitional cells enter the
thymic medulla, and then “zoom” around the medulla at
high speed. Recent studies using multiphoton microscopy
of T cells in lymph node and thymic organ cultures have
shown that they travel at an average velocity of 14  m per
min, and can reach peak velocities of 40  m per min (33–
36). If newly generated medullary T cells also locomote
like this they could potentially interact with 1,000–5,000
Mtecs in 1 d. Therefore, medullary thymocytes would
have plenty of chances to find and be deleted by rare TSA-
expressing Mtecs.
We show for the first time that professional, BM-derived
DCs in the thymus can acquire TSAs from Mtecs and
present epitopes to developing CD4 and CD8 T cells to
enforce self-tolerance. For OT-II CD4 T cells, this profes-
sional uptake and presentation is absolutely essential for tol-
erance induction. On the other hand, CD8 T cell tolerance
was induced directly by Mtecs as well as indirectly by DCs.
At this point we do not propose a general rule where Mtecs
can delete CD8 but not CD4 T cells. Instead, we favor the
hypothesis that Mtecs can induce tolerance in T cells with
high TCR–self-peptide/MHC avidity and the CD8 T cells
we analyzed, but not the OT-II T cells, fall within this
range. DCs, on the other hand, delete T cells that fall into a
broader avidity range. How do thymic DCs acquire anti-
gen from Mtecs? In the periphery, CD8   DCs are adept
at phagocytosing dead or dying cells and cross-presenting
foreign antigen to T cells (37). The same subset of DCs also
presents cell-associated self-antigen produced by islet cells
in the lymph nodes draining the pancreas (38). This subset
of DCs seems designed to present cell-associated antigen,
and thymic DCs belong to this same subset. Thymic DCs
may acquire TSAs by engulfing apoptotic Mtecs, or
from healthy Mtecs in a process referred to as “nibbling,”
whereby browsing DCs take membrane-enclosed blebs
from the surface of viable cells (39). Finally, Mtecs may re-
lease small vesicles called exosomes that could be taken up
by DCs (40).
Our results provide a snapshot of a dynamic and sound
thymic environment where Mtecs are uniquely suited to
synthesize TSA, and DCs are designed to capture and
present TSA to delete autoreactive T cells. This relation-
ship between Mtecs and DCs has evolved to maximize the
impact of negative selection.
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